ABCL News and Press, AbCellera Biologics Inc. From 11/09/22

Summary AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its pla...

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q3 2022 Earnings Call Nov 08, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript ...

AbCellera Biologics Inc (ABCL) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer and President Andrew Booth - Chief Financial Officer ...

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2022 Q3 earnings call. For further details see: AbCellera Biologics Inc. 2022 Q3 - Results - Earnings Call Presentation

AbCellera Biologics press release ( NASDAQ: ABCL ): Q3 GAAP EPS of $0.08 beats by $0.03 . Revenue of $101.38M beats by $18.02M . For further details see: AbCellera Biologics GAAP EPS of $0.08 beats by $0.03, revenue of $101.38M beats by $18.02M

Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per sh...

AbCellera Biologics ( NASDAQ: ABCL ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close. The consensus EPS Estimate is $0.04 (+150.0% Y/Y) and the consensus Revenue Estimate is $83.36M (+1412.9% Y/Y). Over the last 3 months, EPS e...

Summary So far in 2022, aggressive growth names across the board have continued to be hammered into oblivion with very few pockets of strength. Since my last update, somehow, I have managed to thoroughly beat the markets in my aggressive portfolio thanks to sizable outperformances...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 3:50 p.m. Pacific Time (6:50 p.m. Eastern Time) Stifel 2022 Heal...

AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The pa...